A study of rate of volumetric regeneration of liver after liver resection and its correlation with platelets and synthetic liver function tests: a single tertiary care centre experience

Background: Aim of our study was to evaluate the impact of pre and postoperative platelet counts and synthetic liver function tests on liver regeneration and its correlation with CT volumetry in patients undergoing liver resections with curative intent.Methods: All major and minor liver resections (maximum 30) between July 2016 and May 2019 at our hospital were included in the study according to the inclusion criteria and patients who had data available on preoperative, 2 weeks and 2 months postoperative platelet counts, synthetic liver function tests as well as triple phase CECT images, were identified retrospectively and these tests will be done for patients who are included prospectively.Results: The rate of regeneration expressed as % RFLR is proportional to the extent of resection. It was less than 20% in WLE and less than 100% in left lobe resections and 100 to 300% in patients undergoing right hepatectomies and extended right hepatectomies. There was no statistically significant effect of sex, age, BMI, serum albumin, platelet count, INR, preoperative chemotherapy and presence of cirrhosis on percentage of regeneration as well as rate of regeneration. However, perioperative low serum albumin and platelet count had statistically significant effect on mortality (p<0.001).Conclusions: We conclude that; greater the extent of liver resection, faster is the rate of regeneration. Perioperative low serum albumin and platelet counts have significant effect on mortality.

Download Full-text

Transfusion for Hemolysis, Elevated Liver Function Tests, and Low Platelet Count in Pregnancy

Obstetric Anesthesia Digest ◽

10.1097/00132582-200512000-00026 ◽

2005 ◽

Vol 25 (4) ◽

pp. 196

Author(s):

&NA;

Keyword(s):

Platelet Count ◽

Liver Function ◽

Liver Function Tests ◽

Function Tests ◽

Low Platelet Count ◽

Elevated Liver Function Tests ◽

In Pregnancy

Download Full-text

A clinical study on nimesulide hepatotoxicity

International Journal of Research in Medical Sciences ◽

10.18203/2320-6012.ijrms20184215 ◽

2018 ◽

Vol 6 (11) ◽

pp. 3523

Author(s):

Manju K. Nair ◽

Rema M. N. ◽

Shenoy K. T.

Keyword(s):

Liver Function ◽

Adverse Effects ◽

Serum Albumin ◽

Tertiary Care ◽

Liver Function Tests ◽

Tertiary Care Centre ◽

Function Tests ◽

Serum Aspartate Aminotransferase ◽

History Of Use ◽

Blood Routine

Background: Hepatic injury can occur with the use of nimesulide, a non steroidal anti-inflammatory drug. This study was done to evaluate the hepatic and renal functions in patients with rheumatological complaints receiving nimesulide for 2 weeks.Methods: Fifty patients with rheumatological complaints treated at orthopaedic outpatient clinic of a tertiary care centre with nimesulide 100mg twice daily were enrolled in this study. The sociodemographic details, details of comorbidities, history of use of alcohol or tobacco, indication for treatment with nimesulide etc. were recorded in a predesigned proforma. All patients were followed up for two weeks and reviewed at the end of each week for any gastrointestinal adverse effects, changes in blood routine, liver function tests and renal function tests. Data collected was entered in Microsoft Excel 2010, analysed and results were expressed as mean and standard deviation.Results: Out of the fifty patients analysed, mean age was 39 years. 66 % were males. Among liver function tests, only serum albumin and serum aspartate aminotransferase (SGPT) were altered after treatment with nimesulide. Blood urea nitrogen, serum creatinine and blood routine remained normal. No gastrointestinal adverse effects were noted.Conclusions: Nimesulide produced changes in serum albumin and SGPT levels without prominent gastrointestinal or renal adverse effects.

Download Full-text

The impact of total parenteral nutrition on liver function tests in patients with cancer

Cancer ◽

10.1002/1097-0142(19820315)49:6<1249::aid-cncr2820490629>3.0.co;2-d ◽

1982 ◽

Vol 49 (6) ◽

pp. 1249-1257 ◽

Cited By ~ 20

Author(s):

Lawrence D. Wagman ◽

Michael E. Burt ◽

Murray F. Brennan

Keyword(s):

Liver Function ◽

Parenteral Nutrition ◽

Total Parenteral Nutrition ◽

Liver Function Tests ◽

Patients With Cancer ◽

Function Tests ◽

The Impact

Download Full-text

Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy

Internal and Emergency Medicine ◽

10.1007/s11739-020-02425-w ◽

2020 ◽

Vol 15 (8) ◽

pp. 1399-1407 ◽

Cited By ~ 3

Author(s):

Marco Vincenzo Lenti ◽

◽

Federica Borrelli de Andreis ◽

Ivan Pellegrino ◽

Catherine Klersy ◽

...

Keyword(s):

Internal Medicine ◽

Intensive Care ◽

Liver Function ◽

Laboratory Data ◽

Liver Function Tests ◽

Gamma Glutamyl Transpeptidase ◽

Function Tests ◽

Altered Liver ◽

The Impact ◽

Internal Medicine Unit

Abstract Little is known regarding coronavirus disease 2019 (COVID-19) clinical spectrum in non-Asian populations. We herein describe the impact of COVID-19 on liver function in 100 COVID-19 consecutive patients (median age 70 years, range 25–97; 79 males) who were admitted to our internal medicine unit in March 2020. We retrospectively assessed liver function tests, taking into account demographic characteristics and clinical outcome. A patient was considered as having liver injury when alanine aminotransferase (ALT) was > 50 mU/ml, gamma-glutamyl transpeptidase (GGT) > 50 mU/ml, or total bilirubin > 1.1 mg/dl. Spearman correlation coefficient for laboratory data and bivariable analysis for mortality and/or need for intensive care were assessed. A minority of patients (18.6%) were obese, and most patients were non- or moderate-drinkers (88.5%). Liver function tests were altered in 62.4% of patients, and improved during follow-up. None of the seven patients with known chronic liver disease had liver decompensation. Only one patient developed acute liver failure. In patients with altered liver function tests, PaO2/FiO2 < 200 was associated with greater mortality and need for intensive care (HR 2.34, 95% CI 1.07–5.11, p = 0.033). To conclude, a high prevalence of altered liver function tests was noticed in Italian patients with COVID-19, and this was associated with worse outcomes when developing severe acute respiratory distress syndrome.

Download Full-text

Diagnosis experiences from 50 hepatitis B patients in Chongqing, China: a qualitative study

BMC Public Health ◽

10.1186/s12889-021-11929-9 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xiangxi Zhou ◽

Fan Zhang ◽

Yongping Ao ◽

Chunli Lu ◽

Tingting Li ◽

...

Keyword(s):

Hepatitis B ◽

Liver Function ◽

Healthy Lifestyle ◽

Signs And Symptoms ◽

Liver Function Tests ◽

Irreversible Damage ◽

Function Tests ◽

Professional Mental Health ◽

The Impact

Abstract Background The aim of this study was to provide recommendations for reducing the impact of hepatitis B infection on patients with chronic hepatitis B by describing their experiences during the diagnosis process. Methods We conducted face-to-face interviews with 50 hepatitis B patients recruited by convenient sampling from an infectious diseases department of a teaching hospital in Chongqing, China from July to August 2019. Thematic analysis framework included interviewees’ social demographic characteristics, diagnosis approach, signs and symptoms before diagnosis, feelings after diagnosis, and doctor’s instructions. Results Most patients first detected hepatitis B through various types of physical examinations when the patients were asymptomatic or had only mild symptoms. Most patients were shocked, scared, or overwhelmed when they were diagnosed with hepatitis B. They were able to remember the doctor’s instructions about maintaining a healthy lifestyle, but not impressed by the doctor’s advice about regular follow-up liver function tests. The lack of regular follow-up has caused irreversible damage to some patients. Conclusions Most patients are passively diagnosed with hepatitis B due to their lack of awareness on active hepatitis B prevention. Patients need professional mental health care to overcome the negative emotions that following the diagnosis. Physicians’ instruction should emphasize the importance of regular follow-up liver function tests in addition to a healthy lifestyle.

Download Full-text

Comparison of Liver Function Tests in Normal Pregnancy with Non-pregnant Matched Controls

TAJ Journal of Teachers Association ◽

10.3329/taj.v33i1.49820 ◽

2020 ◽

Vol 33 (1) ◽

pp. 17-24

Author(s):

M Rokeya Khatun ◽

Amina Khatun ◽

Md Nowshad Ali

Keyword(s):

Liver Function ◽

Serum Albumin ◽

Pregnant Women ◽

Liver Function Tests ◽

Albumin Concentration ◽

Third Trimester ◽

Serum Globulin ◽

College Hospital ◽

Cross Sectional ◽

Function Tests

Background: Change of liver biochemical profiles is normal during pregnancy. It is almost impossible to understand disease processes that can threaten women during pregnancy without understanding normal physiological change. Aim of this study is to evaluate changes in serum liver function tests in normal pregnant women in first, second and third trimester. Material and Methods: The cross-sectional comparative study was carried out in the Department of Obstetrics & Gynaecology of Rajshahi Medical College Hospital, Bangladesh in 2019. This study consists of 90 pregnant women and 90 matched control. Among the 90 pregnant women, 30 were in first trimester, 30 were in second trimester and 30 were in third trimester. Blood samples were taken for routine liver function and protein profiles Results: Serum total and direct bilirubin concentrations were significantly lower in second and third trimester. The mean ALP level was slightly increased in 2nd trimester and drastically increased in 3rd trimesters during pregnancy. Serum ALT and AST activity was significantly increased in third trimester. No significant change in serum total proteins concentration, but serum albumin concentration was significantly lower and serum globulin concentration was significantly higher in all three trimester. Serum albumin/globulin ratio was significantly reduced in second and third trimester. Conclusion: Relative values of various liver function tests during gestational trimesters appear to be the best guide to confirm the diagnosis and treatment strategies. Thus, gynecologists should routinely monitor liver function tests in all gestational trimesters to avoid the future complications to mother and offspring. TAJ 2020; 33(1): 17-24

Download Full-text

Prevalence of HCV-Helicobacter pylori co-infection and its effects on liver function enzymes of patients in Lahore, Pakistan

BioScientific Review ◽

10.32350/bsr.0103.02 ◽

2019 ◽

Vol 01 (03) ◽

pp. 09-14

Author(s):

Sohaib Bin Wahid ◽

Muhammad Waqar ◽

Zobaria Rehman ◽

Muhammad Wasim ◽

Muhammad Idrees

Keyword(s):

Helicobacter Pylori ◽

Liver Function ◽

Blood Count ◽

Liver Enzymes ◽

Complete Blood Count ◽

Liver Function Tests ◽

Morbidity And Mortality ◽

Function Tests ◽

H Pylori ◽

The Impact

Helicobacter pylori and HCV are the most prevalent pathogens worldwide associated with high rates of morbidity and mortality. This study aimed to determine the prevalence of H. pylori in HCV infected patients and compares changes in liver function tests (LFTs) of both HCV mono-infected and HCV/H. pylori co-infected patients. Eighty-seven participants participated in this study who were first screened for HCV using GeneXpert technology followed by H. pylori antigen stool test. A complete blood count (CBC) analysis and LFTs were performed to determine the impact of HCV and H. pylori on liver enzymes. Our findings suggested that 45% of patients had HCV mono-infection, whereas 55% were co-infected with both HCV and H. pylori. Furthermore, we also observed that ALT, AST, and ALP levels were significantly elevated in HCV/H. pylori co-infected patients as compared to HCV mono-infected patients. To the best of our knowledge, this is the first study to report the prevalence of H. pylori in HCV infected subjects of Lahori population

Download Full-text

Tocilizumab and liver injury in patients with COVID-19

Therapeutic Advances in Gastroenterology ◽

10.1177/1756284820959183 ◽

2020 ◽

Vol 13 ◽

pp. 175628482095918 ◽

Cited By ~ 1

Author(s):

Gaetano Serviddio ◽

Rosanna Villani ◽

Giovanni Stallone ◽

Giulia Scioscia ◽

Maria Pia Foschino-Barbaro ◽

...

Keyword(s):

Liver Injury ◽

Liver Function ◽

Signal Transduction Pathway ◽

Liver Function Tests ◽

Drug Induced ◽

Hypoxemic Respiratory Failure ◽

Acute Hypoxemic Respiratory Failure ◽

Function Tests ◽

Elevated Liver Enzymes ◽

The Impact

Current mortality rate in patients with COVID-19 disease is about 2%, whereas 5% of patients require admission to the intensive care unit. It is assumed that interleukin (IL)-6 may be involved in the pathogenesis of severe COVID-19 infections; therefore, in the absence of a specific antiviral therapy, some authors have suggested that tocilizumab – a drug used to block the signal transduction pathway of IL-6 – could have beneficial effects in the management of severe COVID-19 disease. However, mild-to-moderate elevation in transaminases and drug-induced liver injury have been observed in patients treated with tocilizumab. We present seven cases of patients with elevated liver enzymes [up to five times the upper limit of normal (ULN)] at baseline who received tocilizumab for life-threatening COVID-19 disease. All patients had no history of liver or pulmonary disease and were admitted for acute hypoxemic respiratory failure, dyspnea and fever due to COVID-19 bilateral pneumonia. IL-6 was available in six patients, and was significantly increased particularly in those with severe impairment of lung function. All patients received tocilizumab (8 mg/kg/day) for two consecutive days because of lack of improvement after hydroxychloroquine, azithromycin and lopinavir/ritonavir treatment. After tocilizumab administration, clinical condition rapidly improved and liver function test normalized within 3 weeks of treatment. Tocilizumab may be effective for the treatment of severe COVID-19 disease, even in patients with elevated liver function tests. Further studies are needed to evaluate the impact of tocilizumab use on liver function tests in patients with pre-existing chronic liver disease.

Download Full-text